Find Clinical Trial

Home » Find Clinical Trials » Efficacy and safety of 3 doses of S 47445 versus placebo in patients with Alzheimer’s disease at mild to moderate stages with depressive symptoms. A 24-week international, multi-centre, randomized, double-blind, placebo-controlled phase II study in monotherapy followed by an optional 28-week extension period in co-administration with donepezil.

Efficacy and safety of 3 doses of S 47445 versus placebo in patients with Alzheimer’s disease at mild to moderate stages with depressive symptoms. A 24-week international, multi-centre, randomized, double-blind, placebo-controlled phase II study in monotherapy followed by an optional 28-week extension period in co-administration with donepezil.

← Back

Study Phase	Phase 2

Therapeutic Area	Neuropsychiatric Diseases

Indication	Alzheimer's disease

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	S047445

Active Substance Code	S047445

Protocol Code	CL2-47445-011

EudraCT Code	2014-001519-38

NCT Code	NCT02626572

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.